Correction to: d-Amphetamine Transdermal System in Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Secondary Endpoint Results and Post Hoc Effect Size Analyses from a Pivotal Trial,by Cutler et al. J Child Adolesc Psychopharmacol 2023;33(5):176–182;doi: 10.1089/cap.2023.0005

In the June 2023 issue of Journal of Child and Adolescent Psychopharmacology (vol. 33, no. 5; 176–182), the article titled d-Amphetamine Transdermal System in Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Secondary Endpoint Results and Post Hoc Effect Size Analyses from a Pivotal Trial, by Cutler et al. requires correction.

In the original article, the first sentence of the Clinical Significance section appeared as:

“Methylphenidate and amphetamines have shown high efficacy in treating ADHD in children and adolescents.”

It should have appeared as:

“Methylphenidate and amphetamines have shown high efficacy in treating ADHD in children and adolescents ; however, approximately 40% of patients with ADHD respond to only one of these drugs, indicating the need for additional treatment options, including multiple formulations. ”

The online version of the article has been corrected to reflect this. The publisher apologizes for the error.